Natalizumab

CAS No. 189261-10-7

Natalizumab ( —— )

Catalog No. M23864 CAS No. 189261-10-7

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 224 In Stock
5MG 383 In Stock
10MG 615 In Stock
25MG 897 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Natalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
  • Description
    Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    α4β1 integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    189261-10-7
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.
molnova catalog
related products
  • RGDS peptide

    RGDS peptide (Arg-Gly-Asp-Ser) is a integrin binding sequence that inhibits integrin receptor function, a tetrapeptide analogue of the cell attachment site of fibronectin.

  • Cyclo(-RGDfK) TFA

    Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

  • RGD peptide GRGDNP

    RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and can induce apoptosis in the absence of signals and integrin-mediated cell clustering.